0000000000856376

AUTHOR

Adriana Trapani

showing 5 related works from this author

Realization of polyaspartamide-based nanoparticles and in vivo lung biodistribution evaluation of a loaded gucocorticoid after aerosolization in mice

2016

Abstract In this study, novel polymeric nanoparticles (NPs) were developed and their potential as carriers for beclomethasone dipropionate (BDP) into the lung after aerosolization was demonstrated by in vivo studies in mice. In particular, these NPs were obtained starting from two polyaspartamide-based copolymers which were synthesized by chemical reaction of α,β-poly(N-2-hydroxyethyl)- dl -aspartamide (PHEA) and its pegylated derivative (PHEA-PEG2000) with poly(lactic acid) (PLA). To obtain nanosized particles, the high pressure homogenization (HPH)—solvent evaporation method was followed by using an organic phase containing both PHEA-PLA and PHEA-PEG2000-PLA (at a weight ratio equal to 1:…

polymeric nanoparticles beclomethasone dipropionate aerosolization in miceBiodistributionDrug Evaluation PreclinicalPolymeric nanoparticles Beclomethasone dipropionate (BDP) PolyhydroxyethylaspartamidePharmaceutical ScienceNanotechnology02 engineering and technology010402 general chemistry01 natural scienceschemistry.chemical_compoundMicePulmonary surfactantIn vivoPEG ratioAdministration InhalationmedicineAnimalsTissue DistributionGlucocorticoidsLungAerosolizationAerosolsChromatographyLungmedicine.diagnostic_testtechnology industry and agricultureBeclomethasonerespiratory system021001 nanoscience & nanotechnology0104 chemical sciencesLactic acidBronchoalveolar lavagemedicine.anatomical_structurechemistryNanoparticles0210 nano-technologyPeptidesBronchoalveolar Lavage Fluid
researchProduct

Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier

2015

Gene therapy, i.e. the delivery and expression of therapeutic genes, holds great promise for congenital and acquired respiratory diseases. Non-viral vectors are less toxic and immunogenic than viral vectors, although they are characterized by lower efficiency. However, they have to overcome many barriers, including inflammatory and immune mediators and cells. The respiratory and airway epithelial cells, the main target of these vectors, are coated with a layer of mucus, which hampers the effective reaching of gene therapy vectors carrying either plasmid DNA or small interfering RNA. This barrier is thicker in many lung diseases, such as cystic fibrosis. This review summarizes the most impor…

Pulmonary and Respiratory MedicineCystic FibrosisGenetic enhancementContext (language use)Gene deliveryVectors in gene therapyPolyethylene GlycolsViral vectorPolyethyleinimine Poly-L-lysine Ethylene glycol Chitosan PAMAM G0 dendrimer N-(1-(23-Dioleyloxy)propyl)-NNNtrimethylammonium chloride 12-Dioleoylphosphatidylethanolamine N-acetylcystein 12-Dioctadecanoyl-sn-glycero-3-phosphoethanolaminemedicineHumansTechnology PharmaceuticalPharmacology (medical)RNA Small InterferingLungExpectorantsInflammationLungbusiness.industryBiochemistry (medical)Gene Transfer TechniquesGenetic TherapyMucusMucusmedicine.anatomical_structureSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoImmunologyNanoparticlesInflammation MediatorsbusinessPlasmidsRespiratory tract
researchProduct

In vitro evaluation of glycol chitosan based formulations as oral delivery systems for efflux pump inhibition.

2017

Recently, we have reported that glycol chitosan (GCS) was able to reverse the P- glycoprotein (P-gp) efflux pump. The objective of the present study was to evaluate the potential of two GCS-based dosage forms (aqueous solution or nanoparticle suspension) for oral administration of the P-gp substrate Rho-123. A further aim of the present study was to assess the effect of the glycol chitosan-4-thiobutylamidine thiomer (GCS-TBA) on P-gp activity considering that the corresponding thiomer of chitosan series is a well-known P-gp inhibitor. Pre-treatment of Caco-2 cell monolayer with a GCS solution or GCS-based nanoparticles increased the absorptive transport of Rho-123 across the monolayer of 1.…

endocrine systemATP Binding Cassette Transporter Subfamily BPolymers and Plastics02 engineering and technologyPharmacologyDosage formChitosan03 medical and health scienceschemistry.chemical_compoundGlycols0302 clinical medicineDrug Delivery SystemsOral administrationhealth services administrationpolycyclic compoundsMaterials ChemistryHumansGlycol chitosan-based formulations P-gp inhibition properties Rhodamine 123 Glycol chitosan-4-thiobutylamidine thiomer Caco-2 cells Oral bioavailabilityChitosanChemistryThiomerOrganic ChemistryGlycol chitosan-based formulations P-gp inhibition properties Rhodamine 123 Glycol chitosan-4-thiobutylamidine thiomer Caco-2 cells Oral bioavailability021001 nanoscience & nanotechnologyBioavailabilityCaco-2Settore CHIM/09 - Farmaceutico Tecnologico Applicativo030220 oncology & carcinogenesisNanoparticlessense organsEffluxCaco-2 Cells0210 nano-technologyhormones hormone substitutes and hormone antagonistsConjugateCarbohydrate polymers
researchProduct

Hyaluronic acid and its derivatives in drug delivery and imaging: Recent advances and challenges.

2015

Hyaluronic acid (HA) is a biodegradable, biocompatible, nontoxic, and non-immunogenic glycosaminoglycan used for various biomedical applications. The interaction of HA with the CD44 receptor, whose expression is elevated on the surface of many types of tumor cells, makes this polymer a promising candidate for intracellular delivery of imaging and anticancer agents exploiting a receptor-mediated active targeting strategy. Therefore, HA and its derivatives have been most investigated for the development of several carrier systems intended for cancer diagnosis and therapy. Nonetheless, different and important delivery applications of the polysaccharide have also been described, including gene …

Diagnostic ImagingCarbon nanotubes; Drug delivery; Hyaluronic acid; Intracellular delivery; Quantum dots; TheranosticsPolyestersCarbon nanotubesAcrylic ResinsPharmaceutical ScienceTumor cellsNanotechnologyPolyethylene Glycolschemistry.chemical_compoundDrug Delivery SystemsPolylactic Acid-Polyglycolic Acid CopolymerHyaluronic acidMedicineHumansLactic AcidHyaluronic Acidbusiness.industryQuantum dotsNanotubes CarbonHydrogelsGeneral MedicineIntracellular deliveryBiocompatible materialTheranosticschemistryDrug deliveryDrug deliveryNanocarriersbusinessPolyglycolic AcidBiotechnologyEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
researchProduct

Nanocarriers for respiratory diseases treatment: Recent advances and current challenges

2014

Pulmonary delivery of locally-acting drugs encapsulated in nanocarriers provides several advantages for the treatment of respiratory diseases such as asthma, chronic obstructive pulmonary diseases, cystic fibrosis, tuberculosis and lung cancer. These advantages include, among others, sustained drug delivery to the lungs, reduced therapeutic dose and improved patient compliance. The aim of this review is to give an updated overview on recent advances recorded in the last few years in this field as well as on the major challenges still existing and that remain to be overcome before any clinical application. After an outline on the cellular and extracellular barriers affecting drug delivery to…

Drugmedicine.medical_specialtymedia_common.quotation_subjectpulmonary deliveryAntitubercular AgentsMicrobial Sensitivity TestsGene deliveryPharmacologyCystic fibrosisTherapeutic indexDrug DiscoverymedicineAnimalsHumansTuberculosisIntensive care medicinemedia_commonDrug CarriersLungrespiratory diseasesbusiness.industryMycobacterium tuberculosisGeneral Medicinemedicine.diseaseinhalation of polymeric- and lipid-based nanocarriermedicine.anatomical_structurelung targetingTargeted drug deliveryDrug deliverymucus penetrationNanoparticlesNanocarriersbusinessDefense mechanism
researchProduct